Antibody–drug conjugates, or ADCs, are transforming cancer therapy by combining the precision of monoclonal antibodies with the potency of cytotoxic drugs. In this episode, we explore the science behind ADC design, including the choice of antibody backbones, linker technologies, and payload classes.
We also look at lessons learned from early market withdrawals, the resurgence of re-engineered therapies, and how bystander effects shape clinical outcomes. With more than 15 approvals, ADCs represent one of the fastest-growing classes in oncology. Tune in to learn how scientific innovation and careful design choices are shaping the future of targeted cancer treatment.
Featured Article: Antibody–Drug Conjugates (ADCs): Current and Future Biopharmaceuticals
Podden och tillhörande omslagsbild på den här sidan tillhör
The BioDisruptors. Innehållet i podden är skapat av The BioDisruptors och inte av,
eller tillsammans med, Poddtoppen.
